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a  b  s  t  r  a  c  t
Generalized  anxiety  disorder  (GAD)  can  be treated  effectively  with  either  disorder-speciﬁc  cognitive
behavior  therapy  (DS-CBT)  or transdiagnostic  CBT  (TD-CBT).  The  relative  beneﬁts  of  DS-CBT  and  TD-CBT
for  GAD  and  the  relative  beneﬁts  of delivering  treatment  in  clinician  guided  (CG-CBT)  and  self-guided
(SG-CBT)  formats  have  not  been  examined.  Participants  with  GAD  (n  =  338)  were  randomly  allocated  to
receive  an  internet-delivered  TD-CBT  or DS-CBT  intervention  delivered  in either  CG-CBT  or  SG-CBT  for-
mats. Large  reductions  in symptoms  of  GAD  (Cohen’s  d ≥ 1.48;  avg.  reduction  ≥ 50%)  and  comorbid  major
depressive  disorder  (Cohen’s  d  ≥ 1.64;  avg.  reduction  ≥ 45%),  social  anxiety  disorder  (Cohen’s  d ≥ 0.80;
avg.  reduction  ≥  29%)  and  panic  disorder  (Cohen’s  d ≥  0.55;  avg.  reduction  ≥  33%)  were  found  across
the conditions.  No substantive  differences  were observed  between  DS-CBT  and TD-CBT  or  CG-CBT  andransdiagnostic
isorder-speciﬁc
elf-guided
linician-guided
nternet
4-Month follow-up
SG-CBT,  highlighting  the  public  health  potential  of  carefully  developed  TD-CBT  and  SG-CBT.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).andomized controlled trial
. Introduction
Generalized anxiety disorder (GAD) is a common anxiety disor-
er characterized by chronic and uncontrollable worry (American
sychiatric Association, 2013). The 12-month prevalence of GAD
n Australia and the United States is 2.7% and 3.1%, respectively,
Kessler et al., 2008; Slade et al., 2009) and GAD has a projected
ifetime prevalence of 9.1% (McEvoy et al., 2011). However, large
umbers of people experience subclinical levels of worry that sig-
iﬁcantly interferes with daily functioning (Whiteford et al., 2013)
nd GAD is frequently comorbid with other anxiety disorders and
epression (Hoffman et al., 2008).
GAD can be treated effectively with psychological treatments
uch as cognitive behavioural therapy (CBT), which can be adminis-
∗ Correspondence author at: eCentreClinic, Department of Psychology, Macquarie
niversity, New South Wales, Australia. Fax: +612 9850 8062.
E-mail address: blake.dear@mq.edu.au (B.F. Dear).
ttp://dx.doi.org/10.1016/j.janxdis.2015.09.003
887-6185/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).tered face-to-face (Butler et al., 2006a; Cuijpers et al., 2008; Stewart
& Chambless, 2009; Cuijpers et al., 2014a) and via the internet and
workbooks (Titov et al., 2009a; Robinson et al., 2010; Paxling et al.,
2011; Andersson et al., 2012; Andersson & Titov, 2014; Titov et al.,
2014a,b; Dear et al., 2015b; Titov et al., 2015a; Titov et al., in press).
CBT aims to reduce vulnerability to emotional dysregulation by
helping patients understand the antecedents, consequences, and
patterns of cognitive and behavioral symptoms of psychological
disorders, and teaches skills designed to reduce the prevalence of
unhelpful patterns of thought and behavior.
CBT interventions are typically designed to target symptoms
of one disorder at a time (i.e., disorder-speciﬁc CBT) (McEvoy
et al., 2009; McManus et al., 2010; Titov et al., 2012). How-
ever, it is unclear whether this is the optimal approach given
the high comorbidity between anxiety and depressive disorders.
Several alternative treatment approaches, such as tailored and
transdiagnostic treatments, have recently emerged with the aim
of simultaneously treating both principal and comorbid disorders.
Tailored approaches modify the treatment according to patient
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ymptom characteristics and comorbidities (Carlbring et al., 2011)
nd there is now some emerging evidence of their equivalence to
isorder-speciﬁc approaches (Berger, Boettcher, & Caspar, 2014).
n contrast, transdiagnostic approaches are designed to target com-
on  underlying symptoms and predisposing psychological factors
or anxiety and depression without tailoring (Barlow et al., 2004;
cEvoy et al., 2009; McHugh et al., 2009; Titov et al., 2012).
he conceptual basis of transdiagnostic treatments is informed by
vidence that anxiety and depressive disorders share several char-
cteristics including common symptoms, overall course, response
o treatment, and temperamental antecedents (Barlow et al., 2004;
oldberg, 2010). Transdiagnostic treatments also offer potential
ragmatic advantages over disorder-speciﬁc treatments including
impliﬁed treatment planning for both clinicians and patients and
ncreased cost efﬁciencies (McHugh et al., 2009; Titov et al., 2012).
Results from several clinical trials indicate that internet-
elivered transdiagnostic CBT is clinically effective for GAD
Johnston et al., 2011; Titov et al., 2013; Dear et al., 2015b) and
raditional face-to-face transdiagnostic CBT is effective for comor-
id anxiety and depressive disorders (Ellard, Fairholme, Boisseau,
archione, & Barlow, 2010; Norton & Barrera, 2012; Norton et al.,
013; Farchione et al., 2012). However, despite their potential, few
tudies have directly compared the clinical efﬁcacy or acceptabil-
ty of transdiagnostic with disorder-speciﬁc CBT treatments. One
ecent study (n = 46) randomly allocated participants to receive
ither a single transdiagnostic CBT treatment or to one of three
isorder-speciﬁc treatments for social anxiety, GAD, and panic dis-
rder with allocation determined by the participant’s principal
isorder (Norton & Barrera, 2012). All treatments were adminis-
ered in a face-to-face group format and, while both treatments
ere effective, non-inferiority analyses did not reveal signiﬁcant
ifferences between the two approaches. Similarly, a recent ran-
omized controlled trial (RCT) allocated participants (n = 290) with
epression to receive either disorder-speciﬁc or transdiagnostic
BT and to receive treatment with or without clinician guidance
Titov et al., in press). Each treatment comprised 5 online lessons,
hich were delivered over 8 weeks, and all participants reported
igniﬁcant improvements in symptoms of depression, GAD, social
nxiety and panic disorder, which were maintained at 24-month
ollow-up (Titov et al., in press). Importantly, no substantive differ-
nces were observed between participants who received either the
isorder-speciﬁc or transdiagnostic treatment, or between those
ho did or did not receive clinician guidance, at post-treatment,
-month follow-up, 12-month follow-up or 24-month follow-up.
he ﬁndings of these recent studies provide support for the trans-
iagnostic approach but additional large trials are required to
etermine the reliability and clinical beneﬁts of this approach com-
ared with disorder-speciﬁc treatments for a broad range of anxiety
nd depressive disorders.
The present study extends this work by exploring the relative
linical efﬁcacy and acceptability of transdiagnostic and disorder-
peciﬁc CBT for GAD when provided in both clinician-guided
nd self-guided formats. Participants (n = 338) were randomized
o receive either transdiagnostic treatment (TD-CBT) or disorder
peciﬁc (DS-CBT) treatment for symptoms of GAD, in either a
linician-guided format (CG-CBT) or self-guided format (SG-CBT).
oth treatment options consisted of 5 lessons of internet-delivered
BT (iCBT) delivered over 8 weeks. Participants were assessed prior
o treatment, immediately post-treatment, and at 3, 12, and 24-
onths after treatment. It was hypothesized that both TD-CBT and
S-CBT would result in signiﬁcant reductions in symptoms of GAD,
ut that TD-CBT would be superior at reducing symptoms of comor-
id depression, social anxiety and panic at each time point. It was
lso hypothesized that CG-CBT would be superior to SG-CBT at
very time point for both symptoms of generalized anxiety and
omorbid depression, social anxiety, and panic symptoms. Disorders 36 (2015) 63–77
2. Method
2.1. Participants
Participants read about the study and applied to participate via
the website of the eCentreClinic (www.ecentreclinic.org), which is
a specialist research unit that provides information about common
mental health disorders and offers free psychological treatment via
participation in clinical trials. The study was promoted via adver-
tisements in major newspapers across Australia and via unpaid
general advertisements by a broad range of non-governmental
organizations providing services to people with mental health dif-
ﬁculties. This study was  advertised alongside three other studies
with the same design, with each RCT targeting people with one of
four principal diagnoses, that is, GAD, major depression, panic dis-
order or social anxiety disorder. Interested individuals were invited
to submit an online application to participate in the trial, which
involved completing several symptom questionnaires, and provid-
ing basic demographic information and contact details.
Five-hundred and twenty-ﬁve people applied online to partici-
pate in the trial and indicated that symptoms of GAD were their
principal difﬁculty. Four-hundred and thirty-six of these appli-
cants met  the initial inclusion criteria and then participated in
a telephone interview during which the Mini International Neu-
ropsychiatric Interview Version 5 (MINI) (Lecrubier et al., 1997)
was administered and the inclusion criteria assessed. A further 70
applicants indicated principal difﬁculties of depression, social anx-
iety, or panic during the online application but, upon interview,
indicated GAD was their principal difﬁculty. The inclusion criteria
for the study were: (i) resident of Australia aged 18–64 years of age;
(ii) a principal complaint of GAD symptoms; (iii) total score ≥5 on
the GAD-7 indicating at least mild symptoms (Spitzer et al., 2006);
and (iv) if taking medication for anxiety or depression, being on
a stable dose for at least one month. The exclusion criteria were:
(i) experiencing an unmanaged psychotic illness; (ii) experiencing
very severe symptoms of depression (i.e., deﬁned as a total score
>22 or endorsing a score >2 to item 9 of the Patient Health Question-
naire 9-item (PHQ9); (iii) having a history of self-harm or suicide
within the last 12 months; and (iv) currently participating in CBT.
The CONSORT ﬂowchart for this trial is shown in Fig. 1.
A total of 366 applicants met  the inclusion criteria and were ran-
domly allocated to receive one of the two  treatment approaches:
Transdiagnostic CBT (TD-CBT) or disorder-speciﬁc CBT (DS-CBT).
Participants were also randomly allocated to receive one of the
two delivery formats: clinician-guided CBT (CG-CBT) or self-guided
CBT (SG-CBT). Randomization involved a permuted block random-
ization sequence, with interviewers blind to randomization until
participants were accepted into the study. The demographic char-
acteristics of the resultant sample are shown in Table 1. The study
was approved by the Human Research Ethics Committee (HREC)
of Macquarie University, Sydney, Australia, and the trial was reg-
istered on the Australian and New Zealand Clinical Trials Registry
(ANZCTR) as ACTRN12612000433808.
2.2. Design and measures
The study employed a CONSORT-revised compliant RCT where
participants were randomized to receive one of two  treatment
approaches (treatment approach: TD-CBT vs DS-CBT) and one of
two support formats (support format: CG-CBT vs SG-CBT). All
participants completed questionnaires at initial assessment, pre-
treatment, post-treatment and at 3, 12, and 24-month follow-up.
The primary and secondary measures were administered at each
time point with the exception of the PDSS-SR, which due to an
administrative error was  not administered at initial assessment
but was administered at all other time-points. In addition, the
B.F. Dear et al. / Journal of Anxiety Disorders 36 (2015) 63–77 65
Fig. 1. Participant ﬂow from application to 24-month follow-up.
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Table 1
Demographic characteristics of the participants.
Treatment approach Support format
Overall TD-CBT DS-CBT Signiﬁcance CG-CBT SG-CBT Signiﬁcance
(n  = 338) (n = 170) (n = 168) (n = 168) (n = 170)
Gender
Male 82 (24%) 43 (25%) 39 (23%) Wald’s 2 = .20, 40 (24%) 42 (25%) Wald’s 2 = .04,
Female  256 (76%) 127 (75%) 129 (77%) p = .656 128 (76%) 128 (75%) p = .848
Age  (years)
Mean (SD) 43.78 (11.29) 44.33 (10.71) 43.22 (11.86) Wald’s 2 = .83, 44.53 (11.73) 43.04 (10.83) Wald’s 2 = 1.47,
Range  19,65 19,63 19,65 p = .363 19,65 18,63 p = .224
Marital status
Single/never married 66 (20%) 36 (21%) 30 (18%) Wald’s 2 = .1.06, 34 (20%) 32 (19%) Wald’s 2 = .72
Married/ De Facto 227 (67%) 114 (67%) 113 (67%) p = .301 115 (68%) 112 (66%) p = .395
Separated/divorced/widowed 45 (13%) 20 (12%) 25 (15%) 19 (11%) 26 (15%)
Education
High  school or less 39 (12%) 27 (16%) 12 (7%) Wald’s 2 = 8.59, 22 (13%) 17 (10%) Wald’s 2 = .43,
Trade/technical certiﬁcate 59 (17%) 34 (20%) 25 (15%) p = .003 29 (17%) 30 (18%) p = .511
Diploma/degree 240 (71%) 109 (64%) 131 (78%) 117 (70%) 123 (72%)
Employment
Full  time/part time 249 (76%) 129 (76%) 120 (71%) Wald’s 2 = .75, 115 (68%) 134 (79%) Wald’s 2 = 5.46,
Student 17 (5%) 7 (4%) 10 (6%) p = .385 7 (4%) 10 (6%) p = .019
Unemployed, retired or disabled 240 (71%) 34 (20%) 38 (23%) 46 (27%) 26 (15%)
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SPrevious mental health treatment 227 (67%) 117 (69%) 110 (65%) 
Currently taking medication 90 (27%) 50 (29%) 40 (24%) 
AD-7 and PHQ-9 were also administered weekly during treat-
ent. To reduce burden on participants the tertiary outcomes were
ot administered at initial assessment and the K-10 and NEO-FF-N
ere not administered at 24-month follow-up. All analyses, except
hose for the PDSS-SR and the tertiary measures, used the initial
ssessment scores as baseline. MINI diagnostic assessments were
onducted via telephone at initial assessment and again at 3-month
ollow-up. The study was powered for comparisons between the
wo treatment approaches and between the two delivery formats.
he researchers sought to recruit at least 102 participants for each
omparison arm (i.e., TD-CBT vs DS-CBT and CG-CBT vs SG-CBT)
hich, with alpha set at 0.05 and power set at 0.80, would enable
he detection of small effect size differences between the arms
i.e., Cohen’s ds > .35). Speciﬁcally, 204 participants were sought
or the TD-CBT and DS-CBT comparisons and for the CG-CBT and
G-CBT comparisons. However, more participants were recruited
o address both expected treatment withdrawal and questionnaire
on-response at post-treatment time points.
.2.1. Primary measure
Generalized anxiety disorder 7-Item scale (GAD-7; Spitzer et al.,
006).
The GAD-7 is a 7-item measure of the symptoms and sever-
ty of general anxiety, which is based on the DSM-IV diagnostic
riteria for GAD (Löwe et al., 2008). The GAD-7 has good inter-
al consistency and good convergent and divergent validity with
ther anxiety and disability scales (Kroenke et al., 2010a; Dear et al.,
011). Scores range from 0 to 21 and Cronbach’s  ˛ in the current
tudy was .87.
.2.2. Secondary measures
Patient health questionnaire-9 Item scale (PHQ-9; Kroenke et al.,
001a)
The PHQ-9 is a 9-item measure of symptoms of depression based
n the DSM-IV diagnostic criteria for major depressive disorder
Kroenke et al., 2001b). The PHQ-9 has good internal consistency
Titov et al., 2011) and is sensitive to change (Kroenke et al., 2010b).
cores range from 0 to 27 and Cronbach’s  ˛ in this study was .84.
Mini-social phobia inventory (MINI-SPIN; Connor et al., 2001).’s 2 = .43, p = .512 112 (67%) 115 (68%) Wald’s 2 = .037, p = .848
’s 2 = 1.35, p = .245 40 (24%) 50 (29%) Wald’s 2 = 1.35, p = .245
The 3-item MINI-SPIN is a measure of social anxiety symptoms
based on DSM-IV criteria for social anxiety disorder (Connor et al.,
2001; Weeks et al., 2007). The MINI-SPIN has good internal con-
sistency and adequate convergent validity with other standardized
measures of social anxiety (Weeks et al., 2007; Osório et al., 2010).
Scores range from 0 to 12 and Cronbach’s  ˛ in this study was  .88.
Panic disorder severity scale—self report (PDSS-SR; Houck et al.,
2002).
The PDSS-SR is a 7-item measure of panic disorder symp-
toms. Psychometric evaluations suggest that it has high internal
consistency, good test-retest reliability and is sensitive to
treatment-related change (Houck et al., 2002). Scores range from 0
to 28 and Cronbach’s  ˛ in the current study was .92.
2.2.3. Tertiary measures
Kessler 10-item scale (K-10; Kessler et al., 2002).
The K-10 is a ten-item measure of general psychological distress
with total scores ≥22 associated with a diagnosis of anxiety and
depressive disorders (Andrews & Slade, 2001). Scores range from 0
to 50 and Cronbach’s  ˛ in the current study was  .87.
Sheehan disability scale (SDS; Sheehan, 1983).
The SDS is a 3-item measure of disability with high internal
consistency (Leon et al., 1997). Scores range from 0 to 30 and Cron-
bach’s  ˛ in the present study was .85.
NEO-ﬁve factor inventory—neuroticism subscale (NEO-FFI-N;
Costa & McCrae, 1985).
The neuroticism subscale of the NEO is a 12-item measure of
a general tendency to experience negative emotional states and
sensitivity to stress (Clark et al., 1994; Grifﬁth et al., 2010), which
is considered a higher-order risk factor for anxiety and depression
(Cuijpers et al., 2005; Spinhoven et al., 2009). Scores range from 0
to 48 and Cronbach’s  ˛ in the current study was .77.
2.2.4. Other measures
Mini international neuropsychiatric interview version 5.0.0(MINI; Lecrubier et al., 1997).
The MINI is a brief diagnostic interview developed to determine
the presence of current Axis-I disorders using DSM-IV diagnostic
criteria. It has excellent inter-rater reliability and adequate concur-
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World Health Organization, 1990).
.2.5. Treatment satisfaction and acceptability
Consistent with previous research (Titov et al. 2013; Dear et al.
015a), treatment satisfaction and acceptability was  assessed at
ost-treatment via two questions: (1) ‘would you feel conﬁdent in
ecommending this treatment to a friend?’ and (2) ‘was it worth
our time doing the course?’ Participants responded to these ques-
ions with a ‘Yes’ or ‘No’ response.
.3. Interventions
All participants received access to either a DS-CBT course for
AD, the Worry Course,  or a TD-CBT course, the Wellbeing Course.
he Worry Course was developed speciﬁcally for this trial. The
ellbeing Course has been previously demonstrated as clinically
fﬁcacious in treating symptoms of anxiety and depression (Titov
t al. 2012, 2013, 2014). The two courses were based on the Mac-
uarie University Model (MUM)  of internet-delivered CBT, which
as developed over a large number of clinical trials by the eCentre-
linic research group, and which is associated with high completion
ates, strong clinical outcomes, and high participant satisfaction
e.g., Titov et al., 2013, 2014, 2015; Dear et al., 2015a,b; Titov
t al., in press). Characteristics of this model include a high level
f treatment structure, a combination of didactic teaching meth-
ds with detailed clinical case narratives, scaffolded content which
uilds in detail over the course of treatment, homework assign-
ents designed to facilitate skill acquisition, systematic release of
aterials over a pre-deﬁned period of treatment, and regular and
rotocolized support provided by a combination of clinician con-
act via telephone or email as well as via automated emails and
hort message service prompts that encourage the practice of skills
nd their adoption into day-to-day routines.
To facilitate comparisons the two courses comprise a simi-
ar structure and similar amounts and forms of content. Both
nclude 5 lessons delivered online over 8 weeks, lesson summaries
nd homework assignments for each lesson, a similar number of
etailed case stories, and a similar number of additional resources
argeting symptoms such as sleep problems and communication
kills. Each lesson is presented in a slide format combining text
nd images, with approximately 60 slides per lesson and 50 words
er slide. Automated analyses of readability indicate the required
eading age of the text is 9–10 years of age (Titov et al., 2013,
014). Participants are instructed to read lessons in order over 8
eeks. Lessons 1–5 are available at the beginning of weeks 1–7,
espectively. This timetable provides participants with additional
ime for the most complex components of the intervention; namely
kills for managing cognitive and behavioral symptoms. Consis-
ent with standard deﬁnitions (McEvoy et al., 2009), the TD-CBT
ntervention was not designed to treat any speciﬁc psychological
isorder and rather aimed to present a broad range of therapeu-
ic information and skills relevant to the cognitive, physical and
ehavioral symptoms of psychological distress generally. Reﬂect-
ng this, the TD-CBT treatment did not mention speciﬁc diagnoses
nd all vignettes, examples and case stories were presented to
over a broad range of situations and types of psychological distress
e.g., excessive worry, low mood, social anxieties and panic and
trong physical sensations). In contrast, the DS-CBT treatment was
peciﬁcally designed to target symptoms of GAD and presented all
herapeutic information and skills in the context of GAD and reduc-
ng GAD symptoms. Consequently, all vignettes, examples and case
tories focussed on GAD and the management of associated symp-
oms and no speciﬁc mention of other diagnoses or the broader
pplication of therapeutic skills was made. Thus, the core differ-
nce between the transdiagnostic and disorder-speciﬁc treatment Disorders 36 (2015) 63–77 67
courses was the way in which the content was  presented and taught
rather than the actual skills taught. The content and differences
between the TD-CBT and DS-CBT interventions are summarized in
Table 2.
Participants in the clinician-guided condition (CG-CBT) received
weekly contact from a psychologist using telephone or a secure
email messaging system, based on the preferences of the par-
ticipant. Three accredited and nationally registered psychologists
provided treatment and all had either Masters Degrees or Doctoral
Degrees in clinical psychology. Based on the ﬁndings of previ-
ous studies (Craske et al., 2009; Johnston et al., 2011) and to
minimize therapist drift (Waller, 2009), the nature of the con-
tact was  protocolized and key aims included: (1) reinforcing the
main messages of each lesson, (2) answering questions, (3) rein-
forcing progress and skills practice, (4) problem solving the use of
skills, (5) normalizing the challenges of recovery, and (6) obtain-
ing feedback about the participant’s perception and engagement
with the course. Each contact was designed to take ≤10 min, but
more time was  provided when clinically indicated. The psychol-
ogists received training in online interventions via the training
program at the eCentreClinic and received supervision from BFD
and NT during weekly individual and group supervision sessions.
Participants in the self-guided condition did not receive weekly
contact, but were monitored throughout treatment by the clini-
cians. Participants were not explicitly informed their participation
would be closely monitored throughout treatment. However, they
were informed that they were able to contact the clinic if techni-
cal assistance was required or if they were experiencing a mental
health crisis. A research assistant provided technical support for all
participants in the trial.
All participants received an email at the start of the intervention
with guidelines about the course and a recommended timetable for
working through the materials. Consistent with previous research
(Titov et al., 2013, 2014), all participants also received automated
emails at the beginning of each week to inform them about addi-
tional resources and to recommend activities for that week. All
participants also received automatic emails that reinforced their
progress, congratulated them on the completion of lessons, and
reminded them about the availability of new materials when they
had not viewed them within a week of them becoming available.
2.4. Statistical analyses
All analyses were conducted using SPSS version 21. Group dif-
ferences in demographic variables and diagnostic variables were
analysed using binomial and multinomial logistic regression and
general linear models analyses. The alpha signiﬁcance level for
these preliminary analyses was  adjusted from 0.05 to 0.01 as a
partial control for the very large number of analyses conducted.
However, all of the subsequent analyses employed a 0.05 alpha
signiﬁcance level. Participants who did not start the interventions
were not included in any analyses.
The generalized estimation model (GEE) modelling technique
was employed to examine changes in the symptom measures over
time. GEE emphasizes the modelling of change in an average group
effect over time while accounting for within-subject variance with
the speciﬁcation of a working correlation structure. Rather than
creating conditional interpretation with the use of individual inter-
cepts or random slopes, as in traditional mixed linear models, the
primary emphasis in GEE is to directly model the average group-
related change over time (Hubbarb et al., 2010). An exchangeable
working correlation structure and maximum likelihood estimation
was selected, coupled with a robust error estimation for the pur-
poses of model parsimony, for all GEE analyses. All GEE models also
speciﬁed a gamma  distribution with a log link response scale to
address positive skewness in the dependent variable distributions.
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Table 2
Therapeutic content and skills covered within the transdiagnostic Wellbeing Course and disorder-speciﬁc Worry Course.
Transdiagnostic Wellbeing Course Disorder-speciﬁc Worry Course
Lesson Lesson content Primary skills taught Additional resources Lesson content Primary skills taught Additional resources
1 Education about the general prevalence and
symptoms of anxiety and low mood without
mention of speciﬁc disorders. Introduction of a
CBT model and explanation of the functional
relationship between physical, thought and
behavioral symptoms in psychological distress.
Instructions for identifying their own
symptoms and how their symptoms interact.
Transdiagnostic vignettes and examples of
anxiety and low mood symptoms provided.
- Symptom
identiﬁcation
-  Symptom formulation
- Sleep management
- What to do in a
mental health
emergency
- Transdiagnostic case
stories
Education about the prevalence and symptoms
of GAD. Introduction of a CBT model and
explanation of the functional relationship
between physical, thought and behavioural
symptoms in GAD. Instructions for identifying
their own symptoms and how their symptoms
interact. GAD speciﬁc vignettes and examples
of GAD symptoms provided.
- Symptom
identiﬁcation
-  Symptom formulation
- Sleep management
-  What to do in a
mental health
emergency
- GAD case stories
2  Introduction to the basic principles of
cognitive therapy and importance of managing
thoughts to manage anxiety and low mood.
Instructions for monitoring and challenging
thoughts related to anxiety and low mood.
Transdiagnostic vignettes and examples of
thoughts provided.
- Thought monitoring
-  Thought challenging
- Structured problem
solving
- Worry time
- Challenging beliefs
-  Transdiagnostic case
stories
Introduction to the basic principles of
cognitive therapy and importance of managing
thoughts to manage GAD. Instructions for
monitoring and challenging thoughts related
to  GAD. GAD speciﬁc vignettes and examples
of  thoughts provided.
- Thought monitoring
-  Thought challenging
- Structured problem
solving
-  Worry time
- Challenging beliefs
-  GAD case stories
3  Introduction to the physical symptoms of
hyper-arousal and hypo-arousal and their
relationship to anxiety and low mood.
Instructions about controlling physical
symptoms using de-arousal strategies such as
controlled breathing and scheduling pleasant
activities. Transdiagnostic vignettes and
examples of physical symptoms provided.
- Controlled relaxation
- Pleasant activity
scheduling
- Risk calculation,
coping calculation and
shifting attention
- 100 pleasant things to
do
-  Transdiagnostic case
stories
Introduction to the physical symptoms of
hyper-arousal and hypo-arousal and their
relationship to GAD. Instructions about
controlling physical symptoms using
de-arousal strategies such as controlled
breathing and scheduling pleasant activities.
GAD speciﬁc vignettes and examples of
physical symptoms provided.
- Controlled relaxation
-  Pleasant activity
scheduling
- Risk calculation,
coping calculation and
shifting attention
-  100 pleasant things to
do
-  GAD case stories
4  Introduction to the behavioral symptoms of
anxiety and low mood. Explanation of
avoidance and safety behaviors and their
relationship to ongoing distress. Instructions
for graded exposure for safely confronting
fears and increasing activity levels.
Transdiagnostic vignettes and examples of
graded exposure provided.
- Graded exposure - Assertive
communication
- Transdiagnostic case
stories
Introduction to the behavioral symptoms of
GAD. Explanation of avoidance and safety
behaviors and their relationship to GAD.
Instructions for graded exposure for safely
confronting fears and managing excessive
worries. GAD speciﬁc vignettes and examples
of graded exposure provided.
- Graded exposure - Assertive
communication
-  GAD case stories
5  Information about the occurrence of lapses and
the process of recovery from anxiety and low
mood. Information about the signs of relapse
and managing lapses. Instructions for creating
a  relapse prevention plan. Transdiagnostic
vignettes and examples of lapses and lapse
management provided.
- Relapse prevention - Transdiagnostic case
stories
Information about the occurrence of lapses and
the process of recovery from GAD. Information
about the signs of relapse and managing lapses.
Instructions for creating a relapse prevention
plan. GAD speciﬁc vignettes and examples of
lapses and lapse management provided.
- Relapse prevention - GAD case stories
Note: The transdiagnostic course was  designed in such a way that no speciﬁc mention of anxiety or depressive disorder was mentioned throughout the materials, vignettes, examples and case stories. The disorder speciﬁc course
made  speciﬁc mention of GAD and the materials, vignettes, examples and case stories all focussed on GAD.
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mportantly, in the GEE analyses, the model coefﬁcients represent
ultiplicative change in the dependent variable from baseline;
hese coefﬁcients result in a change factor (i.e., exp(ˇ)), which can
e used to calculate the average percentage change of symptoms
rom baseline. Consistent with the principles of intention-to-treat
nalyses, separate GEE models utilizing random intercepts were
mployed to impute missing data. The same approach was used for
he imputation of the missing binary diagnostic values. Speciﬁcally,
robability values were imputed based on an individual’s initial
iagnostic status combined with time by treatment condition esti-
ates and cases demonstrating higher cumulative probability than
he baseline value being imputed as having a diagnosis.
To maximize power and the interpretability of results, the two
reatment approaches and the two support formats were analyzed
eparately; however, to ensure these analyses did not obscure
igher order patterns within the data, all higher order interactions
ere explored ﬁrst. Following these initial explorations, a system-
tic series of analyses were employed to comprehensively compare
he two treatment approaches (TD-CBT vs. DS-CBT) and the two
upport formats (CG-CBT vs. SG-CBT). First, to explore efﬁcacy
cross symptom domains, GEE analyses were conducted on the pri-
ary and secondary outcome variables from baseline to 24-month
ollow-up focussed on the four symptom domains (i.e., general-
zed anxiety, social anxiety, panic and depression) among those
eeting MINI diagnostic criteria for the related disorder (i.e., GAD,
AD, PAN and MDE) at assessment. Second, to explore efﬁcacy in
erms of general psychological distress, disability and neuroticism,
EE analyses were conducted on the tertiary outcomes from base-
ine to 24-month follow-up using the overall sample data. Third,
or the binary outcome variable of diagnostic status, GEE analy-
es were conducted using a binary scale and logit link function
mplementing quasi-likelihood probability estimates at each time
oint between groups. Fourth, to examine the overall cumulative
eduction in comorbid diagnoses, the average count of comorbid
iagnoses was analysed over time and between groups with a
egative binomial probability distribution and a log link function.
inally, to explore acceptability and satisfaction, one-way factorial
NOVAs and chi-square analyses were conducted on the lesson
ompletion and treatment satisfaction data. For comparison and
enchmarking purposes, Cohen’s d effect sizes and 95% conﬁdence
ntervals were calculated for the within-group and between-group
ffects based on the estimated marginal means derived from the
EE models. The average percentage change across time was also
alculated from the GEE analyses for each of the outcome variables
ith 95% conﬁdence intervals.
. Results
.1. Preliminary analyses
.1.1. Baseline differences
Demographic and diagnostic characteristics of the sample are
hown in Table 1. Speciﬁc details of participant ﬂow, treat-
ent attrition, lesson completion and questionnaire response are
hown in Fig. 1. Preliminary analyses did not reveal any differ-
nces between the TD-CBT and DS-CBT groups or the CG-CBT and
G-CBT groups at baseline (ps ≥ .01). The only exception was a
ifference in the proportions with different levels of education
etween the TD-CBT and DS-CBT, where the TD-CBT group had
 marginally higher proportion of participants with lower levels
f educational achievement (p = .003). Comparisons exploring dif-
erences between participants completing and not completing the
uestionnaires at post-treatment indicated that those not com-
leting questionnaires were slightly younger (M diff = 4.76, Wald’s
2 = 8.05, p = .004) and had marginally higher symptoms of depres- Disorders 36 (2015) 63–77 69
sion (PHQ: M diff = 2.51, Wald’s 2 = 8.05, p = .005) and higher
levels of psychological distress (K10: M diff = 2.91, Wald’s 2 = 7.36,
p = .007). No other differences were found.
3.1.2. Clinician time
Consistent with the design, there was  a signiﬁcant difference
in clinician contact time between CG-CBT and SG-CBT groups
(F1,336 = 563.75, p < .001; Cohen’s d = 2.58). The mean clinician
time per participant in CG-CBT group was 33.54 min  (SD = 18.07),
which comprised answering and making calls (total calls = 918;
range = 0–11 calls; mean time = 22.06; SD = 18.87), as well as read-
ing, sending and responding to secure emails (total emails = 873;
range 0–10 messages; mean time = 11.48; SD = 9.20). The mean
total clinician time per participant for SG-CBT was .48 min
(SD = 1.62), which comprised answering and making calls (total
calls = 2; range = 0–2 calls; mean time = .02; SD = 17.27), as well as
reading, sending and responding to secure emails (total emails = 32;
range 0–4 messages; mean time = .48; SD = 1.62). However, this
contact was  primarily concerned with assessing and managing
mental health crises rather than the provision of treatment or
course-related clinical support. No signiﬁcant differences were
found between the TD-CBT and DS-CBT in the amount of clinician
time required (F1,336 = .68, p = .41).
3.1.3. Preliminary test for higher order interactions
The GEE analyses did not reveal any signiﬁcant treatment
approach by support format by time interactions (GAD-7: Wald’s
2 = 4.35, p = .629; PHQ-9: Wald’s 2 = 4.72, p = .580; MINI-SPIN:
Wald’s 2 = 3.56, p = .735; PDSS-SR: Wald’s 2 = 5.38, p = .371). The
GEE analyses also did not reveal any signiﬁcant treatment approach
by support format by time interactions for the tertiary outcomes
(K10: Wald’s 2 = 2.75, p = .601; SDS: Wald’s 2 = 9.92, p = .078;
NEO-FFI-N: Wald’s 2 = 1.92, p = .589).
3.2. Transdiagnostic CBT (TD-CBT) versus disorder-speciﬁc CBT
(DS-CBT)
The means, percentage reductions and effect sizes for the TD-
CBT and DS-CBT groups are shown in Table 3.
3.2.1. Outcomes across the diagnoses
3.2.1.1. Generalized anxiety disorder. Among those who met  diag-
nostic criteria for GAD (n = 291) the GEE analyses indicated a
signiﬁcant effect for time (GAD-7: Wald’s 2 = 834.15, p < .001)
and a signiﬁcant time by treatment approach interaction for GAD
symptoms (GAD-7: Wald’s 2 = 18.54, p = .001). Pairwise compar-
isons indicated there were no differences between the TD-CBT
and DS-CBT groups at post-treatment (p = .701), 3-month follow-
up (p = .803) or 12-month follow-up (p = .132), but did indicate a
difference at 24-month follow-up (p < .001) with the TD-CBT group
reporting fewer symptoms. These comparisons also indicated that
both groups improved from baseline to post-treatment (p < .001)
and from post-treatment to 3-month follow-up (ps = .022–.040)
and that the TD-CBT group’s symptoms improved slightly from
12-month to 24-month follow-up (p = .013).
3.2.1.2. Major depressive disorder. Among those who  met diag-
nostic criteria for MDD  (n = 157) the GEE analyses indicated a
signiﬁcant effect for time (PHQ-9: Wald’s 2 = 510.69, p < .001) and
a signiﬁcant time by treatment approach interaction for depressive
symptoms (PHQ-9: Wald’s 2 = 15.65, p = .004). Pairwise compar-
isons indicated there were no differences between the TD-CBT
and DS-CBT groups at 3-month follow-up (p = .435), but did indi-
cate signiﬁcant differences at post-treatment (p = .019), 12-month
(p = .016) and 24-month follow-up (p = .001) with the TD-CBT
70
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Table 3
Means, percentage change and effect sizes: transdiagnostic (TD-CBT) versus disorder speciﬁc (DS-CBT).
Estimated  marginal  means %  Change  from  baseline Within  group  Cohen’s  d  from  baseline Between  group  Cohen’s  d
Baseline  Post  3  month 12  month 24  month Post  3 month  12  month  24  month  Post  3  month  12  month  24  month  Post  3  month  12  month  24  month
Principal  outcome
Generalized  anxiety  symptomsa
DS-CBT  (n  =  140)  12.69  (4.45)
[11.97, 13.44]
6.25  (3.99)
[5.63,  6.95]
5.56  (4.14)
[4.91,  6.29]
5.48  (3.89)
[4.87,  616]
5.95  (4.30)
[5.28,  6.71]
51%
[45%,  56%]
56%
[50%,  61%]
57%
[51%,  62%]
53%
[47%,  58%]
1.52
[1.25,  1.79]
1.66
[1.38,  1.93]
1.73
[1.45,  2.00]
1.54
[1.27,  1.80]
.04
[−.19,  .27]
.03
[−.20,  .26]
.18
[−.05,  .41]
.48
[.24,  .71]
TD-CBT (n  =  151)  12.36  (4.31)
[11.69, 13.06]
6.07  (4.03)
[5.46,  6.75]
5.44  (4.05)
[.83,  6.12]
4.83  (3.37)
[4.32,  5.40]
4.17,  (3.07)
[3.70, 4.69]
51%
[45%,  56%]
56%
[50%,  61%]
61%
[56%,  65%]
66%
[62%,  70%]
1.51
[1.24,  1.76]
1.66
[1.39,  1.91]
1.95
[1.66,  2.21]
2.19
[1.89,  2.46]
Secondary outcomes
Depression  symptomsb
DS-CBT  (n  =  69) 14.47  (3.80)
[13.60,  15.39]
7.94  (4.15)
[7.02,  8.99]
6.96  (4.50)
[5.98,  8.11]
7.01  (4.64)
[5.99,  8.19]
7.76  (5.00)
[6.66,  9.03]
45%
[38%,  51%]
52%
[44%,  59%]
52%
[43%,  59%]
46%
[38%,  54%]
1.64
[1.24,  2.02]
1.80
[1.40,  2.19]
1.76
[1.36,  2.14]
1.51
[1.12,  1.88]
.38
[.06,  .70]
.13
[−.19,  .44]
.40
[.08,  .72]
.56
[.24,  .88]
TD-CBT (n  =  88) 14.10  (4.00)
[13.29, 14.96]
6.41  (3.93)
[5.64,  7.29]
6.41  (4.28)
[5.58,  7.37]
5.42  (3.31)
[4.77,  6.16]
5.40  (3.42)
[4.73,  6.17]
55%
[48%,  60%]
55%
[48%,  60%]
62%
[56%,  66%]
62%
[56%,  66%]
1.94
[1.57,  2.29]
1.86
[1.50,  2.20]
2.37
[1.97,  2.74]
2.34
[1.94,  2.71]
Social anxiety  symptomsc
DS-CBT  (n  =  59) 7.97  (2.44)
[7.37, 8.61]
5.69  (2.90)
[5.00, 6.48]
4.98  (3.14)
[4.24,  5.85]
4.67  (2.84)
[4.00,  5.45]
4.71  (2.57)
[4.10,  5.41]
29%
[19%,  37%]
37%
[27%,  47%]
41%
[32%,  50%]
41%
[32%,  49%]
.85
[.47,  1.22]
1.06
[.67,  1.44]
1.25
[.85,  1.63]
1.30
[.90,  1.69]
.16
[−.19,  .52]
.20
[−.15,  .56]
.12
[−.24,  .48]
.32
[.04,  .68]
TD-CBT (n  =  63) 7.79  (2.55)
[7.19, 8.45]
5.22  (2.82)
[4.57,  5.96]
4.36  (2.96)
[3.69,  5.16]
4.33  (2.80)
[3.69,  5.08]
3.82  (2.92)
[3.16,  4.61]
33%
[23%,  41%]
44%
[34%,  53%]
44%
[35%,  53%]
51%
[41%,  59%]
.96
[.59,  1.32]
1.24
[.86,  1.62]
1.29
[.90,  1.67]
1.45
[1.05,  1.84]
Panic symptomsd
DS-CBT  (n  =  50)  9.83  (6.23)
[8.25, 11.72]
6.33  (6.61)
[4.74,  8.45]
5.05  (6.91)
[3.46,  7.38]
4.47  (5.89)
[3.10,  6.44]
4.10  (5.49)
[2.83,  5.94]
36%
[14%,  52%]
49%
[25%,  65%]
55%
[35%,  68%]
58%
[40%,  71%]
.55
[.14,  .94]
.73
[.47,  1.13]
.89
[.47,  1.29]
.98
[.556,  1.38]
.07
[−.34,  .48]
−.02
[−.43,  .39]
.09
[−.32,  .50]
.05
[−.36,  .46]
TD-CBT (n  =  42) 10.06  (4.71)
[8.73, 11.59]
5.91  (4.17)
[4.78,  7.32]
5.16  (4.21)
[4.03,  6.60]
4.02  (3.39)
[3.12,  5.19]
3.83  (4.41)
[2.71,  5.42]
41%
[27%,  53%]
49%
[34%,  60%]
60%
[48%,  69%]
62%
[46%,  73%]
.93
[.47,  1.37]
1.10
[.63,  1.55]
1.47
[.98,  1.94]
1.37
[.88,  1.83]
Tertiary outcomes
Disability  and  functioning  (SDS)
DS-CBT  (n  =  168)  12.40  (7.00)
[11.38, 13.51]
7.86  (6.91)
[6.87,  8.98]
6.13  (6.31)
[5.25,  7.17]
5.99  (6.08)
[5.13,  6.99]
4.93  (6.88)
[5.24,  7.35]
37%
[28%,  45%]
51%
[42%,  58%]
52%
[44%,  59%]
50%
[41%,  58%]
.65
[.43,  .87]
.94
[.71,  1.17]
.98
[.75,  1.20]
1.08
[.84,  1.30]
.07
[−.14,  .29]
.06
[−.15,  .28]
.08
[−.14,  .29]
.12
[−.09,  .34]
TD-CBT (n  =  170) 13.28  (7.64)
[12.18, 14.48]
7.36  (6.42)
[6.45,  8.39]
5.77  (5.45)
[5.00,  6.65]
5.53  (5.95)
[4.70,  6.50]
4.20  (4.93)
[3.52,  5.01]
45%
[37%,  51%]
57%
[50%,  62%]
58%
[51%,  65%]
68%
[62%,  74%]
.84
[.62,  1.06]
1.13
[.90,  1.36]
1.13
[.90,  1.36]
1.41
[1.17,  1.65]
Psychological distress  (K-10)
DS-CBT (n  =  168)  25.98  (6.80)
[24.97, 27.04]
19.70  (6..47)
[18.73,  20.70]
17.98  (5.83)
[17.11, 18.88]
17.73  (5.71)
[16.88,  18.62]
–  24%
[20%,  28%]
31%
[27%,  34%]
32%
[28%,  35%]
–  .95
[.72,  1.17]
1.26
[1.03,  1.49]
1.31
[1.07,  1.55]
–  .06
[−.15,  .28]
−.05
[−.26,  .16]
−.04
[−.18,  .25]
–
TD-CBT (n  =  170)  26.05  (7.23)
[24.98, 27.16]
19.30  (6.48)
[18.35,  20.30]
18.27  (6.00)
[17.39, 19.19]
17.51  (5.93)
[16.65,  18.43]
–  26%
[22%,  30%]
30%
[26%,  33%]
33%
[29%,  36%]
–  .98
[.76,  1.21]
1.17
[.94,  1.40]
1.29
[1.05,  1.52]
–
Neuroticism (NEO-FFI-N)
DS-CBT  (n  =  168)  31.63  (7.27)
[30.55,  32.76]
27.28  (8.52)
[26.01,  28.61]
26.17  (8.25)
[24.95, 27.46]
24.88  (8.50)
[23.62,  26.21]
–  14%
[10%,  18%]
17%
[13%,  21%]
21%
[17%,  25%]
–  .55
[.33,  .77]
.70
[.48,  .92]
.85
[.63,  1.07]
–  −.17
[−.38,  .05]
.03
[−.19,  .24]
−.03
[−.25,  .18]
–
TD-CBT (n  =  170)  32.64  (7.12)
[31.59, 33.73]
28.63  (7.76)
[27.48,  29.82]
25.95  (8.23)
[24.74, 27.22]
25.13  (7.58)
[24.02,  26.30]
–  12%
[9%,  16%]
21%
[17%,  24%]
23%
[19%,  26%]
–  .54
[.32,  .75]
.87
[.65,  1.09]
1.02
[.79,  1.25]
–
Note: Standard deviations are shown in round parentheses for the means and 95% conﬁdence intervals are shown in square parentheses. Percentage reductions derived from the model change factor (i.e., 1 − exp(ˇ)) in the model.
Generalized anxiety, depression, social anxiety and panic symptoms were measured with the GAD-7, PHQ-9, MINI-SPIN, and PDSS-SR, respectively.
a Analyses use the data of participants meeting diagnostic criteria for generalized anxiety disorder at assessment.
b Analyses use the data of participants meeting diagnostic criteria for major depressive disorder at assessment.
c Analyses use the data of participants meeting diagnostic criteria for social anxiety disorder at assessment.
d Analyses use the data of participants meeting diagnostic criteria for panic disorder at assessment.
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roup reporting fewer symptoms at each time point. These com-
arisons revealed that both groups improved from baseline to
ost-treatment (p < .001) and that the TD-CBT group’s symptoms
mproved slightly from 3-month to 12-month follow-up (p = .003).
.2.1.3. Social anxiety disorder. Among those who met  diagnostic
riteria for SAD (n = 122) the GEE analyses indicated a signiﬁcant
ffect for time (MINI-SPIN: Wald’s 2 = 190.55, p < .001) but no
igniﬁcant time by treatment approach interaction for social anx-
ety symptoms (MINI-SPIN: Wald’s 2 = 4.17, p = .383). Pairwise
omparisons indicated that both groups improved similarly from
aseline to post-treatment (p < .001) and from post-treatment to
-month follow-up (p < .001).
.2.1.4. Panic disorder. Among those who met  diagnostic criteria
or PD (n = 92) the GEE analyses indicated a signiﬁcant effect for
ime (PDSS-SR: Wald’s 2 = 115.24, p < .001) but no signiﬁcant time
y treatment approach interaction for panic symptoms (PDSS-SR:
ald’s 2 = .89, p = .925). Pairwise comparisons indicated that both
roups improved from baseline to post-treatment (p < .001) and
rom post-treatment to 3-month follow-up (p = .015).
.2.2. Outcomes for general psychological distress, disability, and
euroticism
Across the whole sample (n = 338) the GEE analyses indicated
 signiﬁcant effect for Time (K10: Wald’s 2 = 906.10, p < .001) but
o signiﬁcant time by treatment approach interaction for general
sychological distress (K10: Wald’s 2 = 1.79, p = .616). Pairwise
omparisons indicated that both groups improved from baseline
o post-treatment (p < .001) and from post-treatment to 3-month
ollow-up (p < .001).
Across the whole sample (n = 338) there was a signiﬁcant effect
or time (SDS: Wald’s 2 = 512.51, p < .001) and a signiﬁcant time
y treatment approach interaction for disability (SDS: Wald’s
2 = 16.28, p = .003). Pairwise comparisons indicated there were
o differences between the TD-CBT and DS-CBT groups at post-
reatment (p = .493), 3-month follow-up (p = .568) or 12-month
ollow-up (p = .482), but did indicate a difference at 24-month
ollow-up (p = .002) with the TD-CBT group reporting less disabil-
ty. The comparisons indicated that both groups improved from
aseline to post-treatment (p < .001) and from post-treatment to 3-
onth follow-up (p < .001), and that the TD-CBT group’s symptoms
mproved slightly from 12-month to 24-month follow-up (p = .002).
Across the whole sample (n = 338) there was a signiﬁcant effect
or time (NEO-FFI-N: Wald’s 2 = 400.35, p < .001) but no signiﬁcant
ime by treatment approach interaction for neuroticism (NEO-FFI-
: Wald’s 2 = 5.94, p = .115). These comparisons also indicated that
oth groups improved from baseline to post-treatment (p < .001),
rom post-treatment to 3-month follow-up (p < .001), and from 3-
onth follow-up to 12-month follow-up (p = .002).
.2.3. Changes in diagnostic status
The numbers and changes in the proportion of participants
eeting formal diagnostic criteria at initial assessment and 3-
onth follow-up are shown in Table 5. The GEE analyses of
iagnoses revealed a signiﬁcant effect for time across all of the diag-
oses (GAD: Wald’s 2 = 224.67, p < .001; MDE; Wald’s 2 = 114.71,
 < .001; SAD: Wald’s 2 = 78.52, p < .001; PD: Wald’s 2 = 41.27,
 < .001) and no signiﬁcant time by treatment approach effects
GAD: Wald’s 2 = 0.860, p = .353; MDE: Wald’s 2 = 0.02, p = .882;
AD: Wald’s 2 = 0.63, p = .425) with the exception of panic disor-
er (PD: Wald’s 2 = 6.04, p = .013). Pairwise comparisons revealed
hat the proportion of participants meeting diagnostic criteria for
AD, MDE, SP and PD reduced signiﬁcantly across both groups and
hat the TD-CBT group reported signiﬁcantly fewer diagnoses of PD
t 3-month follow-up. Disorders 36 (2015) 63–77 71
The GEE analyses focusing on average comorbid diagnoses
revealed a signiﬁcant time effect (Wald’s 2 = 122.9, p < .001) but
no time by treatment approach interaction (Wald’s 2 = 3.291,
p = .070). These analyses indicated signiﬁcant reductions in comor-
bid diagnoses amongst both the TD-CBT and DS-CBT groups over
time.
3.2.4. Treatment completion and satisfaction rates
There was no difference in the number of lessons read by the TD-
CBT (M = 4.28; SD = 1.16) and DS-CBT groups (M = 4.32; SD = 1.18) at
post-treatment (F1,336 = .07, p = .795). Of the participants that com-
pleted the evaluation questions at post-treatment, 99% (138/140)
of the TD-CBT group and 97% (133/137) of the DS-CBT group,
reported they would recommend the course to others. Moreover,
97% (136/140) of the TD-CBT group and 98% (134/137) of the DS-
CBT group reported participating in the course was worth their
time. There were no signiﬁcant differences between the groups in
the proportions of participants willing to recommend the course
or ﬁnding the course was  worth their time (2 range = .21–.73; p
range = .394–.646).
3.3. Clinician-guided CBT (CG-CBT) versus self-guided CBT
(DS-CBT)
The means, percentage reductions and effect sizes for the CG-
CBT and SG-CBT groups are shown in Table 4.
3.3.1. Outcomes across the diagnoses
3.3.1.1. Generalized anxiety disorder. Among those who met  diag-
nostic criteria for GAD (n = 291) the GEE analyses indicated a
signiﬁcant effect for time (GAD-7: Wald’s 2 = 811.87, p < .001)
but no signiﬁcant time by support format interaction for GAD
symptoms (GAD-7: Wald’s 2 = 7.17, p = .127). Pairwise compar-
isons indicated that there were no signiﬁcant differences between
the groups at any time point (p range = .066–.919). These compar-
isons also indicated that both groups improved from baseline to
post-treatment (p < .001) and that the SG-CBT group’s scores also
improved from post-treatment to 3-month follow-up (p < .001),
while the CG-CBT group’s scores improved from 3-month follow-up
to 12-month follow-up (p = .019).
3.3.1.2. Major depressive disorder. Among those who  met diag-
nostic criteria for MDD  (n = 157) the GEE analyses indicated a
signiﬁcant effect for time (PHQ-9: Wald’s 2 = 475.66, p < .001) and
a signiﬁcant time by support format interaction for depressive
symptoms (PHQ-9: Wald’s 2 = 14.45, p = .006). Pairwise compar-
isons indicated there were no differences between the groups
at any time point (p range = .081–.926). These comparisons indi-
cated that both groups improved from baseline to post-treatment
(p < .001) and that the SG-CBT group also improved between
post-treatment and 3-month follow-up (p = .004), while the CG-
CBT group improved between 3-month and 12-month follow-up
(p = .016) and then deteriorated between 12-month and 24-month
follow-up (p = .026).
3.3.1.3. Social anxiety disorder. Among those who  met  diagnos-
tic criteria for SAD (n = 122) indicated a signiﬁcant effect for
time (MINI-SPIN: Wald’s 2 = 189.99, p < .001) but no signiﬁcant
time by support format interaction for social anxiety symptoms
(MINI-SPIN: Wald’s 2 = 2.38, p = .666). These comparisons also
indicated that both groups improved similarly from baseline to
post-treatment (p < .001) and from post-treatment to 3-month
follow-up (p < .001).
3.3.1.3. Panic disorder. Among those who met  diagnostic criteria
for PD (n = 92) the GEE analyses revealed a signiﬁcant effect for time
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Table 4
Means, percentage change and effect sizes: clinician-guided (CG-CBT) versus self-guided (SG-CBT).
Estimated  marginal  means %  Change  from  baseline Within  group  Cohen’s  d  from  baseline Between  group  Cohen’s  d
Baseline  Post  3  month 12  month 24  month Post  3 month  12  month  24  month  Post  3  month  12  month  24  month  Post  3  month  12  month  24  month
Principal  outcome
Generalized  anxiety  symptomsa
CG-CBT  (n  =  144)  12.61  (4.40)
[11.93, 13.33]
6.09  (3.96)
[5.49,  6.75]
5.94  (4.63)
[5.24,  6.73]
5.16  (3.55)
[4.63,  5.76]
5.23  (4.36)
[4.58,  5.97]
52%
[46%,  57%]
53%
[47%,  58%]
59%
[54%,  63%]
59%
[53%,  64%]
1.56
[1.29,  1.82]
1.48
[1.21,  1.73]
1.86
[1.58,  2.13]
1.68
[1.41,  1.95]
−.03
[−.26,  .19]
.22
[−.02,  .45]
.01
[−.22,  .24]
.10
[−.12,  .33]
SG-CBT (n  =  147)  12.42  (4.34)
[11.72, 13.16]
6.23  (4.05)
[5.60,  6.94]
5.06  (3.48)
[4.51,  5.67]
5.12,  (3.72)
[4.54,  5.77]
4.83  (3.24)
[4.32,  5.39]
50%
[44%,  55%]
59%
[54%,  64%]
59%
[54%,  63%]
61%
[57%,  65%]
1.47
[1.21,  1.73]
1.87
[1.59,  2.14]
1.81
[1.53,  2.07]
1.98
[1.70  2.26]
Secondary outcomes
Depression  symptomsb
CG-CBT  (n  =  81) 14.45  (4.02)
[13.63, 15.31]
6.73  (3.88)
[5.97,  7.59]
7.17  (4.50)
[6.29,  8.18]
6.09  (3.77)
[5.35,  6.93]
7.02  (4.90)
[6.06,  8.12]
53%
[47%,  59%]
50%
[43%,  56%]
58%
[52%,  63%]
51%
[44%,  58%]
1.96
[1.63,  2.28]
1.68
[1.36,  1.98]
2.17
[1.82,  2.49]
1.61
[1.30,  1.92]
−.18
[−.49,  .13]
.25
[−.07,  .56]
−.02
[−.33,  .30]
.28
[−.04,  .59]
SG-CBT (n  =  76) 14.07  (3.78)
[13.20,  14.99]
7.46  (4.23)
[6.53,  8.53]
6.10  (4.18)
[5.19,  7.17]
6.1  (4.22)
[5.23,  7.23]
5.82  (3.66)
[5.02,  6.75]
47%
[39%,  54%]
57%
[49%,  63%]
56%
[49%,  63%]
59%
[52%,  64%]
1.65
[1.27,  2.01]
2.00
[1.60,  2.38]
1.98
[1.58,  2.35]
2.22
[1.80,  2.61]
Social anxiety  symptomsc
CG-CBT  (n  =  62) 7.79  (2.36)
[7.23, 8.39]
5.22  (2.63)
[4.61,  5.91]
4.72  (3.22)
[3.99,  5.58]
4.45  (3.00)
[3.77,  5.25]
4.19  (2.82)
[3.55,  4.95]
33%
[24%,  41%]
39%
[28%,  49%]
43%
[33%,  52%]
46%
[36%,  54%]
1.03
[.65,  1.40]
1.09
[.70,  1.46]
1.24
[.85,  1.61]
1.38
[.98,  1.77]
−.16
[−.52,  .19]
.04
[−.32,  .39]
−.04
[−.39,  .32]
−.04
[−.40,  .31]
SG-CBT (n  =  60) 7.97  (2.62)
[7.33, 8.67]
5.69  (3.07)
[4.95,  6.52]
4.61  (2.90)
[3.93,  5.41]
4.55  (2.63)
[3.92,  5.27]
4.31  (2.77)
[3.65,  5.07]
29%
[18%,  38%]
42%
[32%,  51%]
43%
[34%,  51%]
46%
[36%,  54%]
.80
[.42,  1.17]
1.22
[.82,  1.60]
1.30
[.90,  1.69]
1.36
[.95,  1.75]
Panic symptomsd
CG-CBT  (n  =  44)  10.18  (4.60)
[8.88, 11.67]
6.83  (4.73)
[5.54,  8.42]
5.78  (5.25)
[4.39,  7.61]
4.86  (4.80)
[3.60,  6.55]
5.04  (5.75)
[3.57,  7.12]
33%
[17%,  46%]
43%
[25%,  57%]
52%
[36%,  65%]
50%
[30%,  65%]
.72
[.28,  1.14]
.89
[.45,  1.32]
1.13
[.67,  1.57]
.98
[.53,  1.41]
.27
[−.15,  .67]
.24
[−.17,  .65]
.27
[−.14,  .68]
.44
[−.02,  .85]
SG-CBT (n  =  48) 9.75  (6.09)
[8.20,  11.60]
5.43  (5.71)
[4.06,  7.27]
4.49  (5.57)
[3.18,  6.33]
3.65  (4.21)
[2.65,  5.02]
2.95  (3.59)
[2.11,  4.14]
44%
[25%,  58%]
54%
[35%,  67%]
63%
[48%,  73%]
70%
[58%,  78%]
.73
[.31,  1.14]
.90
[.47,  1.31]
1.17
[.72,  1.59]
1.36
[.91,  1.79]
Tertiary outcomes
Disability  and  functioning  (SDS)
CG-CBT  (n  =  168)  13.47  (7.14)
[12.43, 14.58]
7.53  (6.49)
[6.61,  8.57]
6.52  (6.12)
[5.66,  7.51]
5.79  (5.92)
[4.96,  6.75]
6.11  (7.04)
[5.14,  7.27]
44%
[36%,  51%]
52%
[44%,  58%]
57%
[50%,  63%]
55%
[46%,  62%]
.87
[.64,  1.09]
1.05
[.81,  1.27]
1.17
[.94,  1.40]
1.04
[.81,  1.26]
−.02
[−.24,  .19]
.19
[−.02,  .41]
.01
[−.20,  .22]
.30
[.09,  .52]
SG-CBT (n  =  170) 12.22  (7.47)
[11.14, 13.42]
7.68  (6.84)
[6.71,  8.79]
5.38  (5.62)
[4.59,  6.31]
5.72  (6.11)
[4.86,  6.73]
4.29  (4.81)
[3.61,  5.08]
37%
[28%,  45%]
56%
[48%,  62%]
53%
[45%,  60%]
65%
[58%,  70%]
.64
[.42,  .85]
1.04
[.81,  1.26]
.95
.73,  1.18]
1.26
[1.03,  1.49]
Psychological distress  (K-10)
CG-CBT (n  =  168)  26.53  (7.21)
[25.46, 27.64]
19.48  (6.26)
[18.56,  20.44]
18.90  (6.35)
[17.97,  19.88]
17.73  (6.08)
[16.84,  18.66]
–  27%
[23%,  30%]
29%
[25%,  32%]
33%
[30%,  37%]
–  1.04
[.81,  1.27]
1.12
[.89,  1.35]
1.32
[1.08,  1.55]
–  −.01
[−.22,  .21]
.26
[−.05,  .48]
.04
[−.18,  .25]
–
SG-CBT (n  =  170)  25.51  (6.76)
[24.50,  26.56]
19.52  (6.68)
[18.53,  20.56]
17.36  (5.37)
[16.56, 18.19]
17.52  (5.56)
[16.69,  18.38]
–  23%
[19%,  27%]
32%
[29%,  35%]
31%
[28%,  35%]
–  .89
[.67,  1.11]
1.34
[1.10,  1.57]
1.29
[1.05,  1.52]
–
Neuroticism (NEO-FFI-N)
CG-CBT  (n  =  168)  32.57  (7.08)
[31.52, 33.65]
28.0  (8.01)
[26.90,  29.31]
26.86  (8.54)
[25.60,  28.17]
25.31  (7.88)
[24.15,  26.52]
–  14%
[10%,  17%]
18%
[13%,  21%]
22%
[19%,  26%]
–  .59
[.37,  .81]
.73
[.51,  .95]
.97
[.74,  1.19]
–  .03
[−.18,  .24]
.19
[−.02,  .41]
.07
[−.14,  .29]
–
SG-CBT (n  =  170)  31.72  (7.31)
[30.63,  32.85]
27.83  (8.33)
[26.59,  29.13]
25.27  (7.86)
[24.10,  26.50]
24.71  (8.20)
[23.50,  25.99]
–  12%
[8%,  16%]
20%
[16%,  24%]
22%
[18%,  26%]
–  .50
[.28,  .71]
.85
[.63,  1.07]
.90
[.68,  1.12]
–
Note: Standard deviations are shown in round parentheses for the means and 95% conﬁdence intervals are shown in square parentheses. Percentage reductions derived from the model change factor (i.e., 1 − exp(ˇ)) in the model.
Generalized anxiety, depression, social anxiety and panic symptoms were measured with the GAD-7, PHQ-9, MINI-SPIN, and PDSS-SR, respectively.
a Analyses use the data of participants meeting diagnostic criteria for generalized anxiety disorder at assessment.
b Analyses use the data of participants meeting diagnostic criteria for major depressive disorder at assessment.
c Analyses use the data of participants meeting diagnostic criteria for social anxiety disorder at assessment.
d Analyses use the data of participants meeting diagnostic criteria for panic disorder at assessment.
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Table 5
Proportions meeting diagnostic criteria over time for each of the groups.
TD-CBT versus DS-CBT CG-CBT versus SG-CBT
Baseline 3 month % Change from baseline Baseline 3 month % Change from baseline
TD-CBT DS-CBT TD-CBT DS-CBT TD-CBT DS-CBT CG-CBT SG-CBT CG-CBT SG-CBT CG-CBT SG-CBT
Diagnosis
Generalized
anxiety disorder
89%
[83%, 93%]
83%
[77%, 88%]
31%
[24%, 38%]
28%
[22%, 35%]
58%
[50%, 66%]
53%
[44%, 62%]
86%
[80%, 90%]
86%
[80%, 91%]
32%
[26%, 40%]
26%
[20%, 34%]
54%
[46%, 60%]
60%
[53%, 66%]
Major  depressive
disorder
52%
[44%, 59%]
41%
[34%, 49%]
11%
[7%, 17%]
7%
[4%, 12%]
41%
[33%, 49%]
34%
[26%, 42%]
48%
[41%, 56%]
45%
[37%, 52%]
8%
[5%, 14%]
10%
[6%, 15%]
40%
[32%, 48%]
35%
[27%, 43%]
Social  anxiety
disorder
37%
[30%, 45%]
35%
[28%, 43%]
8%
[5%, 13%]
10%
[6%, 16%]
29%
[21%, 36%]
25%
[18%, 32%]
37%
[30%, 44%]
35%
[35%, 43%]
10%
[6%, 15%]
9%
[5%, 14%]
27%
[20%, 35%]
26%
[19%, 34%]
Panic  disorder 29%
[23%, 37%]
25%
[19%, 32%]
6%
[3%, 11%]
13%
[8%, 18%]
24%
[16%, 31%]
13%
[5%, 20%]
26%
[20%, 33%]
28%
[22%, 35%]
10%
[6%, 15%]
9%
[5%, 14%]
17%
[10%, 24%]
19%
[12%, 27%]
Comorbid diagnoses
Average 1.18
[1.05, 1.32]
1.01
[0.88, 1.15]
0.39
[0.30, 0.51]
0.46
[0.36, 0.58]
66%
[56%, 74%
54%
[42%, 64%]
1.13
[0.98, 1.26]
1.08
[0.95, 1.22]
0.46
[0.36, 0.59]
0.39
[0.30, 0.51]
58%
[46%, 68%]
64%
[53%, 72%]
Frequencya
0 26%
[20%, 33%]
32%
[26%, 40%]
81%
[74%, 86%]
76%
[69%, 82%]
– – 29%
[23%, 36%]
29%
[23%, 36%]
80%
[74%, 86%]
76%
[70%, 82%]
– –
1  38%
[31%, 46%]
41%
[34%, 49%]
14%
[10%, 20%]
20%
[14%, 26%]
– – 37%
[31%, 45%]
42%
[35%, 49%]
13%
[9%, 19%]
21%
[15%, 27%]
– –
2  28%
[21%, 35%]
20%
[15%, 27%]
5%
[2%, 9%]
2%
[1%, 6%]
– – 26%
[20%, 33%]
22%
[16%, 29%]
5%
[3%, 10%]
2%
[1%, 5%]
– –
3  8%
[5%, 13%]
7%
[4%, 11%]
1%
[0%, 4%]
2%
[1%, 5%]
– – 7%
[4%, 12%]
8%
[4%, 13%]
1%
[0%, 5%]
1%
[0%, 5%]
– –
Note: 95% conﬁdence intervals of estimates are shown in square parentheses both for estimates of proportions of participants meeting diagnostic criteria and for percentage change.
a The frequency of comorbid diagnoses over time was  estimated employing binary logistic regressions, provide estimates of frequency with 95% conﬁdence intervals rather than simple raw counts.
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PDSS-SR: Wald’s 2 = 129.85 p < .001) but no signiﬁcant time by
upport format interaction for panic symptoms (PDSS-SR: Wald’s
2 = 5.93, p = .205). Pairwise comparisons revealed that both groups
mproved similarly from baseline to post-treatment (p < .001) and
rom post-treatment to 3-month follow-up (p = .016).
.3.2. Outcomes for general psychological distress, disability, and
euroticism
Across the whole sample (n = 338) the GEE analyses indicated
 signiﬁcant effect for time (K10: Wald’s 2 = 906.32, p < .001)
ut no signiﬁcant time by support format interaction for general
sychological distress (K10: Wald’s 2 = 10.12, p = .018). Pairwise
omparisons indicated there were no differences between the CG-
BT and SG-CBT groups at post-treatment (p = .956) and 12-month
ollow-up (p = .743), but there was a difference at 3-month follow-
p (p = .016) with the SG-CBT group reporting marginally less
isability. The comparisons indicated that both groups improved
rom baseline to post-treatment (p < .001) and that the SG-CBT
roup’s symptoms improved slightly from post-treatment to 3-
onth follow-up (p < .001), while the CG-CBT group’s symptoms
mproved slightly from 3-month to 12-month follow-up (p = .006).
Across the whole sample (n = 338) there was  a signiﬁcant
ffect for time (SDS: Wald’s 2 = 490.62, p < .001) and a signiﬁ-
ant time by support format interaction for disability (SDS: Wald’s
2 = 13.41, p = .009). Pairwise comparisons indicated there were
o differences between the CG-CBT and SG-CBT groups at post-
reatment (p = .835), 3-month follow-up (p = .076) or 12-month
ollow-up (p = .922), but did indicate a difference at 24-month
ollow-up (p = .005), with the SG-CBT group reporting less disabil-
ty. The comparisons indicated that both groups improved from
aseline to post-treatment (p < .001) and from post-treatment to
-month follow-up (p < .021), and the SG-CBT group’s symptoms
lso improved from 12-month to 24-month follow-up (p < .001).
Across the whole sample (n = 338) there was a signiﬁcant effect
or Time (NEO-FFI-N: Wald’s 2 = 398.59, p < .001) but no signif-
cant time by support format effect for neuroticism (NEO-FFI-N:
ald’s 2 = 5.01, p = .171). Pairwise comparisons indicated that
oth groups improved from baseline to post-treatment (p < .001),
rom post-treatment to 3-month follow-up (p < .001), and from 3-
onth follow-up to 12-month follow-up (p = .002).
.3.3. Changes in diagnostic status
The numbers and changes in the proportion of participants
eeting formal diagnostic criteria at initial assessment and 3-
onth follow-up are shown in Table 5. The GEE analyses of
iagnoses revealed a signiﬁcant effect for time across all of the diag-
oses (GAD: Wald’s 2 = 228.35, p < .001; MDE; Wald’s 2 = 117.83,
 < .001; SAD: Wald’s 2 = 78.82, p < .001; PD: Wald’s 2 = 41.38,
 < .001) and no signiﬁcant time by treatment approach effects
GAD: Wald’s 2 = 0.888, p = .346; MDE: Wald’s 2 = 0.741, p = .389;
AD: Wald’s 2 = 0.001, p = .971; PD: Wald’s 2 = 0.212, p = .645).
airwise comparisons revealed that the proportion of participants
eeting diagnostic criteria for GAD, MDE, SP and PD reduced sig-
iﬁcantly from pre-treatment to 3-month follow-up for both the
G-CBT and SG-CBT groups.
The GEE analyses focused on average comorbid diagnoses
evealed a signiﬁcant time effect (Wald’s 2 = 123.6, p < .001) but
o time by treatment approach interaction (Wald’s 2 = 0.620,
 = .431). These analyses indicated signiﬁcant reductions in comor-
id diagnoses amongst both the CG-CBT and SG-CBT groups over
ime..3.4. Treatment completion and satisfaction rates
The CG-CBT group (M = 4.45; SD = .98) completed slightly more
essons on average than the SG-CBT group (M = 4.15; SD = 1.32) at Disorders 36 (2015) 63–77
the post-treatment time point (F1,336 = 5.84, p = .016). Of the partic-
ipants that completed the evaluation questions at post-treatment,
97% (134/138) of the CG-CBT group, and 99% (137/138) of the SG-
CBT group, reported they would recommend the course to others.
Further, 97% (133/137) of the CG-CBT group and 99% (137/138) of
the SG-CBT group reported the course was  worth their time. There
were no signiﬁcant differences in the proportions of participants
willing to recommend the course or ﬁnding the course was worth
their time (2 range = .69–1.86; p range = .404–.173).
4. Discussion
The aim of the current study was  to compare the clinical efﬁ-
cacy and acceptability of transdiagnostic CBT and disorder-speciﬁc
CBT for GAD when provided in both clinician-guided and self-
guided formats. It was  hypothesized that both TD-CBT and DS-CBT
would result in signiﬁcant improvements on principal symptoms of
GAD, but that TD-CBT would be associated with superior improve-
ments to DS-CBT on comorbid symptoms of depression, social
anxiety, and panic at each time point. It was also hypothesized
that CG-CBT would be superior to SG-CBT on both principal and
comorbid symptoms at each time point. These hypotheses were
not fully supported. All conditions resulted in signiﬁcant improve-
ments across the outcome measures and these corresponded to
signiﬁcant reductions in the proportions of participants meeting
diagnostic criteria. Some statistically signiﬁcant differences were
found between the TD-CBT and DS-CBT groups at longer-term
follow-up, with the TD-CBT group reporting slightly lower levels
of symptoms of generalised anxiety and depression. There was
also some evidence of a greater reduction in PD diagnoses among
the TD-CBT group compared with the DS-CBT group. However, the
differences were relatively small in magnitude and were not consis-
tently observed across the outcome domains or diagnoses. Finally,
no differences were found between participants who  received CG-
CBT or SG-CBT either in terms of symptom scores or changes in
diagnostic status. Treatment completion and satisfaction was high
amongst all groups.
The results of the current trial indicate that TD-CBT and DS-CBT
are both effective at reducing symptoms of GAD with gains sus-
tained for at least 24 months. The magnitude of reductions seen in
the current trial were large (Cohen’s d ≥ 1.51; avg. reduction ≥ 51%)
and consistent with those reported in face-to-face treatments
(Butler et al., 2006b; Stewart & Chambless, 2009; Cuijpers et al.,
2014b) and internet-delivered treatments for GAD (Andrew et al.,
2010). The ﬁndings also indicate that both TD-CBT and DS-CBT
result in large reductions in comorbid symptoms of major depres-
sive disorder (Cohen’s d ≥ 1.64; avg. reduction ≥ 45%), social anxiety
disorder (Cohen’s d ≥ 0.85; avg. reduction ≥ 29%) and panic disorder
(Cohen’s d ≥ 0.55; avg. reduction ≥ 36%). Importantly, these results
were maintained across the follow-up period and are consistent
with the magnitude of improvements reported for disorder-speciﬁc
interventions for these conditions (Butler et al., 2006b; Andrews
et al., 2010; Reinholt & Krogh, 2014).
There was  some evidence of lower levels of generalized anx-
iety, depression and disability at the 24-month follow-up point
among the TD-CBT group compared with the DS-CBT group. This
may  suggest that transdiagnostic treatments increase long-term
resilience to psychological distress and common internalizing dis-
orders. Importantly, while the mechanism by which this would
occur is not clear based on existing data, one conceivable possibility
is that the transdiagnostic approach increases long-term resilience
by encouraging the broad application of therapeutic skills across a
range of symptoms and in the context of a broad range of triggers of
psychological distress. Thus, when new symptoms or psychological
distress arise, patients who  have received transdiagnostic treat-
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ent are more able to employ previously learnt skills than patients
ho received disorder speciﬁc treatments and who  only learnt
o apply therapeutic skills to speciﬁc symptoms. Further research
s needed to examine whether this is the case but it is broadly
onsistent with the rationale and theories supporting transdiag-
ostic treatment (Barlow et al., 2004; Titov et al., 2012). However,
t should also be noted that the clinical differences between TD-
BT and DS-CBT were relatively minor and both treatments were
ssociated with signiﬁcant reductions in symptoms and diagnoses
s well as high levels of treatment completion and treatment sat-
sfaction. Thus, the results of the current study are consistent with
tudies that have compared transdiagnostic and disorder speciﬁc
reatment, and that have not found marked or consistent clinical
utcome differences between the two forms of treatment (Norton
 Barrera, 2012; Titov et al., in press).
The ﬁndings of the current study suggest that the beneﬁts of
ransdiagnostic treatment may  not emerge until long after treat-
ent and, thus, the choice of transdiagnostic treatment may  be
rimarily pragmatic over the short term. For example, as high-
ighted elsewhere (Clark, 2009; Andrews et al., 2010; Norton &
arrera, 2012; Titov et al., 2012), transdiagnostic interventions
emove the requirement for clinical services to offer multiple
isorder-speciﬁc treatments as well as the requirement for thera-
ists to be competent in administering multiple and highly speciﬁc
isorder-speciﬁc treatments. Moreover, because they are suitable
or multiple disorders, transdiagnostic treatments have the poten-
ial to remove the requirement for detailed differential diagnosis
rior to treatment, which can take considerable time and may  delay
he commencement of effective treatment. Thus, as has also been
ighlighted elsewhere, the use of transdiagnostic treatments may
igniﬁcantly assist in efforts to disseminate and increase access to
videnced based psychological treatment (McHugh et al., 2009).
he ﬁndings of the current study support the use of transdiag-
ostic treatment for adults with principal symptoms of GAD and
ymptoms of other comorbid anxiety and depressive disorders.
In the present study, similar clinical outcomes, treatment com-
letion and satisfaction levels were obtained when the treatment
as provided in either clinician-guided or self-guided formats.
hese results are consistent with an emerging number of studies
hat indicate self-guided internet-delivered interventions can be
eveloped to a point where they result in large clinical effects con-
istent with clinician-guided interventions (Berger et al., 2011a,b;
itov et al., 2013; Dear et al., 2015a). These ﬁndings highlight
he public health potential of carefully designed self-guided inter-
entions for reducing the burden of common mental health
onditions, which is unlikely to be addressed via traditional treat-
ent approaches (Kazdin, 2015). However, it is important to note
hat participants in the current trial received a comprehensive tele-
hone assessment prior to treatment, which, while brief, allowed
articipants to ask questions about the treatment and allowed clin-
cians to orient the participant to treatment. It is also important to
ote that all participants received automated emails throughout
reatment, which were carefully designed to guide their progress
nd that have been found to be important in other trials (Titov
t al., 2013, 2014). Participants’ symptoms were also monitored
aily throughout treatment and contact was initiated to ensure
articipants’ safety in the event of signiﬁcant deteriorations in
ymptoms or self-reported safety. These processes, in combination,
re likely to have built therapeutic alliance, conﬁdence, engage-
ent and adherence with the intervention, which are all known to
e important in facilitating clinical outcomes (Martin et al., 2000).
It is also important to note that signiﬁcant reductions in gen-
ral psychological distress (Cohen’s d ≥ 0.89; avg. reduction ≥ 23%),
isability (Cohen’s d ≥ 0.64; avg. reduction ≥ 37%) and neuroticism
Cohen’s d ≥ 0.50; avg. reduction ≥ 12%) were observed and sus-
ained at follow-up across all conditions. The changes observed Disorders 36 (2015) 63–77 75
in neuroticism are consistent with an emerging body of literature
indicating that internet-delivered psychological interventions can
reduce the expression of personality traits associated with emo-
tional vulnerability (Hedman et al., 2014; Titov et al., in press).
Clinical changes in vulnerability factors, such as neuroticism, are
important because they are a strong predictor of impairment,
health service use and psychiatric morbidity and are associated
with considerable economic costs (Lahey, 2009; Cuijpers et al.,
2010). Unfortunately, to date, very little research has examined the
mechanisms through which internet-delivered treatments operate
to reduce psychological disorder and distress. However, the current
ﬁndings suggest that neuroticism may  be a worthwhile factor for
further study.
The present study has a number of strengths and limitations
that should be borne in mind when considering its ﬁndings. The
main limitation of the current trial is the absence of a control group,
which limits the ability to control for general time effects and spon-
taneous remission. However, it is important to note that previous
trials have shown that control groups of people with a diagnosis
of GAD do not improve signiﬁcantly over time without interven-
tion (Titov et al., 2009b; Robinson et al., 2010). It is also important
to note that the current trial was designed and conducted as a
superiority trial and consequently caution is needed in concluding
any statistical ﬁndings as supporting clinical equivalence, which
requires the use of equivalence trial analyses. The current trial
also used the internet as a method for delivering treatment and,
although there is emerging evidence of their equivalennt efﬁcacy
(Andersson, Titov, & Null, 2014), some caution is needed in gen-
eralizing the ﬁndings of the current study to treatments delivered
face-to-face. An important strength of the research design was the
similarity of the disorder-speciﬁc and transdiagnostic treatments
with respect to format and structure, which substantially reduces
the number of key variables that could account for any differential
outcomes. Other notable strengths include the use of a large sample
size, high retention rates, the long-term follow-up of participants as
well as the use of multiple outcomes to comprehensively evaluate
the intervention (e.g., clinical symptoms, diagnostic assessments,
satisfaction and treatment completion).
The present trial found large clinical improvements and high
levels of treatment satisfaction for both transdiagnostic and
disorder-speciﬁc treatment for GAD when delivered in both
clinician-guided and self-guided formats. Clinical improvements
were observed across a broad range of clinical domains and were
largely maintained from post-treatment until 24-month follow-up.
There was some evidence favoring transdiagnostic treatment over
disorder-speciﬁc treatment, but the differences were relatively
small in magnitude, were not consistently observed across mea-
sures, and were only observed at long-term follow-up. No marked
or consistent differences were observed between groups who
received treatment in clinician-guided and self-guided formats.
Thus, together with the results of a similar trial evaluating transdi-
agnostic and disorder-speciﬁc treatment for depression (Titov et al.,
in press), the present study highlights the public health potential of
internet-delivered transdiagnostic treatments in either clinician-
guided or self-guided formats. However, it remains to be seen
whether the ﬁndings of the current trial generalize to other com-
mon  mental disorders, such as panic disorder and social anxiety
disorder. Those questions will be addressed in future trials.
Conﬂict of interestN. Titov and B. Dear are funded by the Australian Government to
develop and provide the MindSpot Clinic, a national online assess-
ment and treatment service for Australian adults with anxiety and
depression.
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